WHO WE ARE

For more than 50 years, Nucro-Technics has been a leading Contract Support Organization for the pharmaceutical, biotech, medical device, and marijuana industries.

WHAT WE DO

Nucro-Technics conducts GMP & GLP-Compliant Chemistry, Microbiology, Toxicology, Genetic Toxicology, and Bioanalytical Testing  to fulfill FDA, Health Canada, and European requirements.

HOW WE CAN HELP

▪ GMP Release Testing
▪ GLP IND-Enabling Studies
▪ Medical Device Testing
▪ Marijuana Testing & Profiling
▪ QA & Regulatory Affairs Consulting

LOOKING TO MEET GMP AND GLP TESTING REQUIREMENTS?

More Than Just a Testing Lab, Nucro-Technics Is Your Contract Testing Laboratory R&D Partner

Nucro-Technics is Canada’s largest privately-owned Contract Research / Contract Support Organization, routinely completing projects for 40 of the 50 biggest pharmaceutical, biotech, and medical device companies worldwide.  With a client base that spans from virtual companies at the Investigation New Drug-enabling stage to multinational conglomerates requiring finished product release testing, Nucro-Technics supports all phases of pharmaceutical development.  Accredited by Health Canada, the FDA, the Standards Council of Canada, and ISO-certified to the 9001: 2015 standard, Nucro-Technics has decades of experience across many therapeutic indications.

COMMON SERVICES OFFERED BY APPLICATION

GMP Finished Product Testing

GLP IND-Enabling Studies

Marijuana Testing

Clinical Trial Support

Proteomics

Stability Studies

News / Updates

  • Pesticide Residue Headling Picture

Pesticide Residue Testing with USP <561>

In order to meet the safety standards enforced by regulatory authorities, food commodities and botanicals are required to undergo pesticide residue testing. The tests described in the U.S. Pharmacopoeia <561> “Articles of Botanical Origin” [...]

  • Pill Bottle

Nitrosamine Impurities Testing With the Updated FDA Guidance

Nitrosamine impurities have recently become a very important topic in the world of pharmaceuticals. Ever since unacceptable levels of this probable carcinogen were detected in common drugs (including angiotension II receptor blockers, Zantac, metformin), [...]